AMCP’s Science & Innovation Theaters provide a structured focus for participants to gain information on specific products, therapeutic areas and/or disease states in presentations provided by company designated presenters. Theaters take place in The Exchange on Wednesday, March 27 and Thursday, March 28.
AMCP Science & Innovation Theaters with a include preapproval information exchange information. Subject to federal laws and regulations, attendance at these sessions is restricted to payors, formulary committee, or other similar entity representatives with knowledge and expertise in the area of health care economic analysis, carrying out responsibilities for the selection of drugs for coverage or reimbursement. For more information, visit our website.
Wednesday, March 27, 2019
A Preventive Migraine Therapy for Patients: Updated Data
Provided by Amgen, Inc.
12:00pm-12:30pm / Theater #1, Hall B2/C
This theater will provide an overview of an approved treatment for prevention of migraine in adults. The program includes a conversation about the approved indication, important safety information, key findings from clinical trials, extended data and other important prescribing information. This program will also explore the clinical development of the treatment and two patient cases—one an episodic migraine patient and the other a chronic migraine patient.
Presenter: Jack Schim, MD, FSHS, UCNS Headache Certification, Co-director, The Headache Center of Southern California, Immediate Past President, The Headache Cooperative of the Pacific
Glaucoma: Current and Investigational Treatment Landscape
Provided by Allergan
12:00pm-12:30pm / Theater #2, Hall B2/C
This session will address an overview of glaucoma and the current treatment landscape. Both medical and pharmaceutical interventions will be discussed. Areas of unmet need will be reviewed, as will investigational products in Allergan’s pipeline which may offer new options to patients with glaucoma.
Presenter: Eric V. Busby, Pharm.D., Associate Managed Care Scientific Director, Allergan
Investigational Treatments in Rheumatology and Dermatology
Provided by AbbVie Medical Affairs
12:45pm-1:15pm / Theater #1, Hall B2/C
- This presentation will provide a clinical overview for two of AbbVie's late stage investigational products being evaluated for rheumatoid arthritis and plaque psoriasis, including the latest phase III clinical trial data. This information is intended to assist payors in planning and budgeting for future coverage and/or reimbursement decisions.
- These investigational products have not established safety and efficacy for any FDA approved use, however they are anticipated to launch in 2019.
- Consistent with existing FDA guidance, attendance will be limited to a “Payor” audience-this audience includes payors, formulary committees (e.g., pharmacy and therapeutics committees), drug information centers, technology assessment panels, pharmacy benefit managers, and other multidisciplinary entities that review scientific and technology assessments to make drug selection formulary management, and/or coverage and reimbursement decisions on a population basis for health care organizations.
Registration is required. To Pre-Register for this event, please click here.
Presenters: Cynthia Holmes, Pharm.D., MS, Scientific Director Dermatology, AbbVie and Jerry Clewell, Pharm.D., MBA, Scientific Director Rheumatology, AbbVie
Economic Burden of Spinal Muscular Atrophy (SMA): Outcomes of Patients Treated with AVXS-101 Gene Therapy versus Natural History
Provided by AveXis, Inc.
12:45pm-1:15pm / Theater #2, Hall B2/C
During this presentation, we will explore the health economic burden of SMA and discuss the findings from the investigational AVXS-101 clinical study data that relate to health outcomes such as the reduced need for ventilator support and reduced hospitalisations that potentially lead to improved quality of life for SMA infants versus Natural History. This presentation addresses an investigational product that has not yet been approved as safe and effective by the Food and Drug Administration or any other regulatory body. This presentation will provide factual information about an investigational product and data developed to date. It is not intended to promote the product for any use. To the extent that this information changes, as further development occurs, this information will be updated.
Presenter: Daniel Malone, RPh, PhD, FAMCP, Professor, College of Pharmacy, University of Arizona
Burden of MS Progression
Provided by Novartis
1:30pm-2:00pm / Theater #1, Hall B2/C
a. The first part of presentation will include the findings based on a retrospective study. The focus will be on economic burden of increasing disability in MS population.
b. The second part of presentation will include results from a phase 3, double blind, placebo controlled trial that evaluated efficacy and safety of siponimod in MS patients with varying level of disability.
Presenters: Kristen Johnson, PhD, HE&OR Neuroscience Lead, Novartis and
Gustavo Suarez Zambrano, MD, Multiple Sclerosis Lead Medical Director, Novartis
Intelligent Interventions: Improving Pharmacy Quality and Financial Outcomes by Matching Outreach to the Member
Provided by RxAnte
1:30pm-2:00pm / Theater #2, Hall B2/C
Discover how health plans, pharmacies, and providers are collaborating in member outreach and getting more from medicines. For nearly a decade, RxAnte has been helping to create more effective outreach initiatives to improve prescribing and adherence; aligning goals among plans, providers, and pharmacies; and creating tools and technologies to support pharmacy- and provider-led interventions. Join this session presented by Kerri Petrin, VP of Client Services at RxAnte, to observe RxAnte programs in the field, and discover how the latest trends in population health are carving out a bigger role for pharmacy-led interventions to medically complex patients.
Presenter: Kerri Petrin, MPH, VP of Client Services, RxAnte
Thursday, March 28, 2019
Evolving Treatment Landscape for Primary Hemophagocytic Lymphohistiocytosis
Provided by Sobi
9:45am-10:15am / Theater #1, Hall B2/C
Primary hemophagocytic lymphohistiocytosis is an ultra-rare, rapidly progressive, often-fatal syndrome of hyperinflammation in which massive hyperproduction of interferon gamma is thought to drive immune system hyperactivation, ultimately leading to multiple organ failures. Diagnosis is challenging due to the variability in signs and symptoms, so increased awareness is important. Treatment options for primary HLH will be discussed. The immediate goal of treatment is to quickly control the hyperinflammation and to prepare for hematopoietic stem cell transplantation.
Presenter: Katherine Miller, PharmD., BCPS, Senior Medical Science Liaison, Sobi, Inc.
The Evolving Landscape For Alzheimer’s Disease
Provided by Biogen and Eisai
9:45am-10:15am / Theater #2, Hall B2/C
As more of the United States population ages, Alzheimer’s disease continues to grow as a national healthcare concern. This session will review the burden of Alzheimer’s disease on the managed care system, as well as identify the potential cost drivers of care. The session will also provide an overview of biomarkers and the evolving understanding of Alzheimer’s disease. Furthermore, with potential new disease-modifying therapies on the horizon, the session will explore the potential impact of early diagnosis and treatment. This program is open only to representatives of payers, formulary committees, or other similar entities who have responsibility for the selection of drugs for coverage or reimbursement.
Presenter: information to come.
Management of Osteoarthritis of the Knee: Update on Clinical and Real-World Considerations
Provided by Flexion Therapeutics
10:30am-11:00am / Theater #1, Hall B2/C
Osteoarthritis (OA) is the most common chronic joint condition in the United States. However, not all patients with OA of the knee are able to achieve pain management and there are substantial medical costs across the course of treatment. This presentation will focus on clinical evidence and real-world data considerations for an extended-release intra-articular injection treatment option.
Presenter: Scott Kelley, MD, Chief Medical Officer, Flexion Therapeutics
Leading CGM innovation with Dexcom G6®- the Only Fully Interoperable, Zero Fingerstick CGM System*
Provided by Dexcom
10:30am-11:00am / Theater #2, Hall B2/C
CGM devices are considered the most significant breakthrough in diabetes management in the past 40 years1 and Dexcom, Inc., headquartered in San Diego, CA, has been a leader of those innovations. The powerful and revolutionary Dexcom G6® is the first CGM to receive the integrated CGM classification by the FDA. Dexcom G6® is approved for use as a standalone CGM and for integration with bluetooth connected insulin pens and automated insulin delivery systems. This presentation will highlight Dexcom’s superior technology, connected ecosystem, Google/Verily partnership, and future developments including EHR integration, population-level insights, and decision support algorithms.
Presenters: Roy Thomas, PharmD, Medical Science Liaison, Managed Markets, Dexcom and Peter Simpson, Vice-President, Advanced Technology, Dexcom
1 Clarke SF and Foster JR. A history of blood glucose meters and their role in self-monitoring of diabetes mellitus. Br J Biomed Sci. 2012;(3)2:83-93.
*If your glucose alerts and readings from the Dexcom G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.